Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.27Last Year’s EPS
-1.12Same Quarter Last Year
Moderate Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -13.80%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Intellia Therapeutics reported strong progress in its clinical pipeline, particularly with Phase III enrollment for HAE and ATTR amyloidosis, and demonstrated a solid financial position to support ongoing operations. However, the company faced increased operating expenses and restructuring challenges, including program discontinuation and workforce reductions.Company Guidance
During Intellia Therapeutics' fourth quarter and full-year 2024 financial results call, the company provided key guidance metrics for its clinical programs and financial outlook. They announced the completion of enrollment for the NTLA-2002 Phase III study for hereditary angioedema (HAELO) in the second half of 2025 and anticipated a BLA filing in 2026. Similarly, for the transthyretin amyloidosis (ATTR) MAGNITUDE study, they expect to exceed 550 patients by the end of 2024, targeting a second BLA filing by 2028. The company's cash position was reported at $861.7 million as of December 31, 2024, down from $1 billion the previous year. They revealed an increase in R&D expenses to $116.9 million for Q4 2024, primarily driven by lead program advancements, and a projected 5% to 10% decline in GAAP operating expenses due to a restructuring plan. Intellia also highlighted a significant increase in collaboration revenue to $12.9 million from negative $1.9 million year-over-year, attributed mainly to the Regeneron license and collaboration agreement.Strong Enrollment in Phase III Trials
Enrollment in Phase III studies for hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR) is progressing well, with expectations to exceed 550 patients by year-end in the MAGNITUDE trial.
Positive Data from Phase I Trials
Phase I data for NTLA-2001 showed a mean serum TTR reduction of 90% at 12 months, indicating potential disease stabilization or improvement for ATTR amyloidosis patients.
Robust Financial Position
Intellia reported approximately $861.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing a solid financial foundation to fund operations into 2027.
Regenerative Medicine Advanced Therapy Designation
Nex-z received FDA's RMAT designation for ATTR amyloidosis, facilitating close collaboration with the FDA towards a BLA filing by 2028.
---
NTLA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NTLA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $10.80 | $10.86 | +0.56% |
| Nov 07, 2024 | $16.06 | $16.00 | -0.37% |
| Aug 08, 2024 | $21.31 | $22.38 | +5.02% |
| May 09, 2024 | $23.00 | $24.86 | +8.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Intellia Therapeutics (NTLA) report earnings?
Intellia Therapeutics (NTLA) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Intellia Therapeutics (NTLA) earnings time?
Intellia Therapeutics (NTLA) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTLA EPS forecast?
NTLA EPS forecast for the fiscal quarter 2025 (Q1) is -1.27.
---